SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

Kodiak Sciences Reports Q3 2026 Net Loss of $66.2 Million, $88.7 Million in Cash

Kodiak Sciences reported a third-quarter 2026 net loss of $66.2 million, or $1.05 per share, compared with a $61.5 million loss a year earlier. Research and development spending rose to $58.3 million, and cash was $88.7 million at quarter-end. After the quarter, it raised $69 million through an at-the-market share offering.

Published:

Updated:

What happened

Kodiak Sciences said its DAYBREAK study met one-year vision goals for Zenkuda and KSI-501, meaning neither treatment performed worse than the comparison on measured vision outcomes. The company plans to seek approval for Zenkuda in three uses in late 2026. Its quarterly loss widened, and it raised money by selling shares.

Global impact / market context

The study result is progress, but it does not show that either treatment was better than the comparison. Kodiak also continues to lose money and use cash. Selling shares brought in money, but it can reduce existing shareholders’ ownership share.

What to watch

  1. Check whether Kodiak files its planned three-use Zenkuda application in the fourth quarter of 2026; this would show whether the stated plan moves ahead.
  2. Check the next reported cash balance and cash use; the company had $88.7 million at quarter-end and reported a $66.2 million quarterly loss.
  3. Check for updates on the DAYBREAK study and its measured vision outcomes; the reported result only says the treatments were not worse than the comparison after one year.

Affected assets

  • Kodiak Sciences Inc.

Evidence